Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review

JC. Ianotto, N. Curto-Garcia, M. Lauermanova, D. Radia, JJ. Kiladjian, CN. Harrison,

. 2019 ; 104 (8) : 1580-1588. [pub] 20190124

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, systematický přehled

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023766

Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children and young adults. We therefore performed a systematic review of cases, published since 2005, concerning patients aged below 20 years at the time of diagnosis of essential thrombocythemia or polycythemia vera. We identified 396 cases of essential thrombocythemia and 75 of polycythemia vera. The median age at diagnosis was 9.3 and 12 years, respectively, and females constituted 57.6% and 45% of the groups, respectively. Half of the patients were asymptomatic at diagnosis. The proportion of so-called triple negativity was high: 57% in essential thrombocythemia and 73% in polycythemia vera. The incidence of thrombosis during the follow-up was 9.3% in patients with polycythemia vera and less, 3.8%, in those with essential thrombocythemia. Venous events were predominant (84.2%), with hemorrhagic episodes being rarer (<5%). The risk of evolution also seemed low (2% to myelofibrosis and no reports of acute leukemia), but the median follow-up was only 50 months. Survival curves were not available. Half of the patients received an antithrombotic drug and 40.5% received a cytoreductive drug. All data should be analyzed with care because of the proportion of missing data (10.7% to 74.7%). This review highlights interesting points concerning this population of young patients with myeloproliferative neoplasms, including that such patients were identified as negative for all common driver mutations, but also shows the need for larger contemporary cohorts with longer follow-up to assess the true prognosis of these patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023766
003      
CZ-PrNML
005      
20201214131116.0
007      
ta
008      
201125s2019 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2018.200832 $2 doi
035    __
$a (PubMed)30679326
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Ianotto, Jean-Christophe $u Department of Haematology, Guy's and St Thomas' NHS Trust, London, UK. Service d'Hématologie Clinique, Institut de Cancéro-Hématologie, Centre Hospitalier Régional et Universitaire de Brest, Brest, France.
245    10
$a Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review / $c JC. Ianotto, N. Curto-Garcia, M. Lauermanova, D. Radia, JJ. Kiladjian, CN. Harrison,
520    9_
$a Although it is well known that myeloproliferative neoplasms occur in younger patients, few large cohorts of such patients have been reported. Thus, our knowledge about circumstances of diagnosis, outcome and treatment is limited, especially for children and young adults. We therefore performed a systematic review of cases, published since 2005, concerning patients aged below 20 years at the time of diagnosis of essential thrombocythemia or polycythemia vera. We identified 396 cases of essential thrombocythemia and 75 of polycythemia vera. The median age at diagnosis was 9.3 and 12 years, respectively, and females constituted 57.6% and 45% of the groups, respectively. Half of the patients were asymptomatic at diagnosis. The proportion of so-called triple negativity was high: 57% in essential thrombocythemia and 73% in polycythemia vera. The incidence of thrombosis during the follow-up was 9.3% in patients with polycythemia vera and less, 3.8%, in those with essential thrombocythemia. Venous events were predominant (84.2%), with hemorrhagic episodes being rarer (<5%). The risk of evolution also seemed low (2% to myelofibrosis and no reports of acute leukemia), but the median follow-up was only 50 months. Survival curves were not available. Half of the patients received an antithrombotic drug and 40.5% received a cytoreductive drug. All data should be analyzed with care because of the proportion of missing data (10.7% to 74.7%). This review highlights interesting points concerning this population of young patients with myeloproliferative neoplasms, including that such patients were identified as negative for all common driver mutations, but also shows the need for larger contemporary cohorts with longer follow-up to assess the true prognosis of these patients.
650    _2
$a mladiství $7 D000293
650    _2
$a asymptomatické nemoci $7 D058070
650    _2
$a dítě $7 D002648
650    _2
$a cytotoxiny $x terapeutické užití $7 D003603
650    _2
$a časná diagnóza $7 D042241
650    _2
$a fibrinolytika $x terapeutické užití $7 D005343
650    _2
$a exprese genu $7 D015870
650    _2
$a krvácení $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D006470
650    _2
$a lidé $7 D006801
650    _2
$a Janus kinasa 1 $x genetika $7 D053613
650    _2
$a Janus kinasa 2 $x genetika $7 D053614
650    _2
$a mutace $7 D009154
650    _2
$a polycythaemia vera $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D011087
650    _2
$a prognóza $7 D011379
650    _2
$a splenomegalie $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D013163
650    _2
$a esenciální trombocytemie $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D013920
650    _2
$a trombóza $x diagnóza $x farmakoterapie $x genetika $x patologie $7 D013927
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a systematický přehled $7 D000078182
700    1_
$a Curto-Garcia, Natalia $u Department of Haematology, Guy's and St Thomas' NHS Trust, London, UK.
700    1_
$a Lauermanova, Marie $u Department of Haematology, Guy's and St Thomas' NHS Trust, London, UK. Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
700    1_
$a Radia, Deepti $u Department of Haematology, Guy's and St Thomas' NHS Trust, London, UK.
700    1_
$a Kiladjian, Jean-Jacques $u Centre d'Investigation Clinique, Hôpital St Louis, Paris, France.
700    1_
$a Harrison, Claire N $u Department of Haematology, Guy's and St Thomas' NHS Trust, London, UK claire.harrison@gstt.nhs.uk.
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 104, č. 8 (2019), s. 1580-1588
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30679326 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131114 $b ABA008
999    __
$a ok $b bmc $g 1596085 $s 1114442
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 104 $c 8 $d 1580-1588 $e 20190124 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...